Calamos Advisors LLC has released its latest 13F-HR filing, revealing a total portfolio value of approximately $33.5 billion as of September 30, 2026. This filing is significant as it provides insights into the company's investment strategies and positions within the financial services industry.

The 13F-HR filing, submitted on November 2, 2026, is a quarterly report that details the holdings of institutional investment managers. It is a crucial tool for investors and analysts looking to understand the investment landscape and trends within the market.

Background

Calamos Advisors LLC is an asset management firm based in Naperville, Illinois. The company specializes in investment management and advisory services. It is known for its focus on growth equity and alternative investments, catering to a diverse clientele, including institutional investors and high-net-worth individuals.

The firm operates under the Central Index Key (CIK) number 0001316507 and has been actively filing with the SEC, with its most recent filings including 13F-HR forms and N-PX forms. The firm is incorporated in Delaware and has a fiscal year ending on December 31.

What the Filing Says

In the recent filing, Calamos Advisors reported a total portfolio value of $33,495,498,309. The filing includes a comprehensive overview of the firm's investment holdings across various sectors. Notably, the company has maintained significant positions in companies such as 10X Genomics Inc, 3M Co, and Abbott Laboratories, among others.

According to the filing, the firm holds 28,116 shares of 10X Genomics valued at approximately $2,540,562, while its investment in 3M Co totals 303,723 shares valued at about $49,856,130. These figures reflect the firm's commitment to investing in innovative and established companies across different industries.

Impact

The filing may affect various stakeholders, including investors, analysts, and competitors within the asset management industry. Investors can gain insights into the firm's investment strategies and potential market trends based on its portfolio composition. Additionally, competitors may analyze Calamos Advisors' holdings to adjust their own strategies and offerings in response to market dynamics.

What's Next

The filing does not specify what happens next for Calamos Advisors LLC. However, stakeholders will likely continue to monitor the firm's future filings and performance as they assess the company's ongoing investment strategies.

Source: SEC Filing, Accession Number 0001316507-26-000004